News | March 03, 2009

Many Patients Implanted with a LVAD ?Develop Right Ventricular Dysfunction?

March 3, 2009 - A recently published article in the Journal of Heart and Lung Transplantation (JHLT) from the German Heart Institute Berlin found right ventricular (RV) dysfunction develops in 20-50 percent of patients after left ventricular assist device (LVAD) implantation, leading to prolonged ICU stays and elevated mortality.

A second article, from the Hospital of the University of Pennsylvania (HUP), found that of 266 LVAD recipients, 99 required a RV assist device (37 percent).

“Right ventricular (RV) failure after left ventricular assist device (LVAD) placement is a serious complication and is difficult to predict,” the HUP article explained. “In the era of destination therapy and the total artificial heart, predicting post-LVAD RV failure requiring mechanical support is extremely important.”

“Right ventricular failure in LVAD patients is tragic,” said Dr. Jack Copeland, chief of cardiothoracic surgery at University Medical Center. “If it can be anticipated, the solution is biventricular support from the start. If it becomes a crisis, in appropriate patients, the CardioWest temporary total artificial heart may be life-saving. By replacing both sides of the dying heart, the CardioWest eliminates complications caused by failing ventricles, diseased valves, ventricle defects and electrical problems requiring a pacemaker and/or defibrillator.”

Both articles were published in the December 2008 issue of JHLT and presented at the 28th annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in April 2008.?

Originally designed as a permanent replacement heart, the CardioWest artificial heart is currently approved as a bridge to human heart transplant for patients dying from end stage biventricular failure.

The CardioWest artificial heart is the only FDA, Health Canada and CE mark approved total artificial heart in the world. There have been more than 780 implants of the CardioWest artificial heart, accounting for more than 150 patient years of life on the device.

For more information: www.SynCardia.com


Related Content

News | Cardiovascular Surgery

Oct. 23, 2024 – The Society for Vascular Surgery (SVS) is launching a three-year patient education campaign, Highway to ...

Home October 23, 2024
Home
News | Cardiovascular Surgery

June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home June 13, 2024
Home
News | Cardiovascular Surgery

June 3, 2024 — Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported ...

Home June 03, 2024
Home
News | Cardiovascular Surgery

May 16, 2024 — A recent publication in the American Heart Association Circulation highlights a comprehensive ...

Home May 16, 2024
Home
News | Cardiovascular Surgery

April 30, 2024 — The expanding use of transcatheter technologies has changed the landscape in the treatment of valvular ...

Home April 30, 2024
Home
News | Cardiovascular Surgery

April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home April 23, 2024
Home
News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
Subscribe Now